Glenmark Pharmaceuticals Limited has announced a schedule of analyst and institutional investor meetings to be conducted between August and September 2026. The company will engage with market participants through physical meetings in Mumbai, covering both group presentations and one-on-one discussions. These engagements are part of the firm’s ongoing efforts to maintain transparency and provide updates to institutional stakeholders, though no Unpublished Price Sensitive Information (UPSI) will be shared during these sessions.

The intimation was issued pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Rashmi Khandelwal, Company Secretary & Compliance Officer of Glenmark Pharmaceuticals Limited, signed the disclosure on August 7, 2026. The company has notified both the National Stock Exchange of India Limited (NSE) and BSE Limited regarding the upcoming schedule. All listed meetings are designated as physical events held in Mumbai, allowing for direct interaction between management and investors.

The scheduled engagements span four major industry conferences over a six-week period. The first event is the Emkay Confluence 2026, scheduled for August 12, 2026. This is followed by the Motilal Oswal 22nd Annual Investor Conference 2026 on August 17, 2026. The calendar resumes in September with the Elara India Dialogue 2026 on September 1, 2026, and concludes with the Kotak Healthcare Forum on September 17, 2026.

The company noted that the schedule remains subject to change due to exigencies on the part of either the investors or the company. Despite the flexibility in scheduling, the format for all four events remains consistent, offering both group and one-on-one meeting options. This approach allows Glenmark Pharmaceuticals to address broader market themes in group settings while providing detailed insights to specific institutional investors in private sessions.

What This Means for Investors

The decision to hold physical meetings across multiple high-profile conferences underscores the company’s commitment to active investor relations. By participating in both generalist forums like Emkay Confluence and specialized platforms like the Kotak Healthcare Forum, Glenmark Pharmaceuticals aims to reach a diverse segment of the investment community. The absence of UPSI disclosures ensures that these meetings serve as informational channels rather than catalysts for immediate price movements based on new material data. Investors are advised to monitor the company’s official filings for any substantive updates following these engagements.

Glenmark Pharmaceuticals Limited has scheduled its 48th Annual General Meeting (AGM) for Friday, September 11, 2026, at 2:00 p.m. IST, to be held exclusively through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The meeting aims to transact business as outlined in the notice, including the approval of financial results for FY25-26 and the declaration of dividends. Shareholders must ensure their KYC details are updated to receive dividends electronically, as mandated by recent regulatory circulars.

The meeting is convened in compliance with the Companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Ministry of Corporate Affairs General Circular No. 03/2025 dated September 22, 2025. Electronic copies of the AGM notice and Integrated Annual Report for FY25-26 will be dispatched to members with registered email IDs as of July 31, 2026. Physical copies can be requested via email to complianceofficer@glenmarkpharma.com .

Key Dates and Voting Schedule

Shareholders are required to adhere to specific timelines for e-voting and dividend eligibility. The cut-off date for determining voting eligibility is Friday, September 04, 2026. Remote e-voting will commence on Tuesday, September 08, 2026, at 9:00 a.m. IST and conclude on Thursday, September 10, 2026, at 5:00 p.m. IST. Votes cast during this window cannot be altered or recast during the live AGM session.

Dividend and KYC Compliance

The Board of Directors, in its meeting on May 29, 2026, recommended a dividend of ₹2.5 per equity share for the financial year ended March 31, 2026, subject to shareholder approval at the AGM. If approved, the dividend will be paid on or after Monday, September 14, 2026, within 30 days of declaration. Payment will be made exclusively through electronic transfer modes to members holding shares as of the record date, August 31, 2026.

Glenmark Pharmaceuticals emphasizes strict adherence to KYC norms. Members holding physical shares must update their PAN, contact details, mobile number, bank account, and signature via Form ISR-1 and ISR-2 submitted to KFin Technologies Limited. Failure to update these details before the cut-off may result in dividend payments being restricted to periods from April 1, 2024, onwards until compliance is achieved. Demat holders are advised to update bank details directly with their Depository Participants.